Incyte Corporation Stock News

INCY vs. TECH: Which Stock Is the Better Value Option?

Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Incyte Corp. INCY, -1.46% said Monday that the Food and Drug Administration approved Opzelura as a topical repigmentation treatment for patients with nonsegmental vitiligo. Vitiligo is an autoimmune d

Incyte is outperforming the SP 500. Institutions are accumulating shares.

Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.

As investors continue grappling with a volatile stock market, five stocks in Catherine Wood (Trades, Portfolio)'s first-quarter 13F equity portfolio that have high GF Scores and have outperformed the

Sometimes, the smart-money move is to dive in on a dip and leave your stocks alone for a decade or more.

Incyte's 1Q 2022 results look solid. Jakafi keeps good revenue growth. Lower gross/net discount in 2H could boost Opzelura net revenue growth.

Two developments could put Incyte Corporation ( INCY , Financial) into the realm of value stocks, in my opinion. First, it eliminated its long-term debt in 2018 (it had carried little or no short-term

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY)

Eli Lilly & Co. LLY, -1.22% and Incyte INCY, +4.80% said Wednesday the Food and Drug Administration has approved the use of their Olumiant for the treatment of certain adults who are hospitalized with

Incyte Corporation's (NASDAQ: INCY) Q1 adjusted EPS reached $0.55, compared to $0.67 posted a year ago. Analysts had estimated $0.68.

Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.

Incyte Corporation (NASDAQ:INCY ) Q1 2022 Earnings Conference Call May 3, 2022 8:00 AM ET Company Participants Christine Chiou – Head-Investor Relations Hervé Hoppenot – Chairman, President and C

Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?